Skip to main content

Coronary Artery Bypass Grafting

Cardiovascular
4
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket

Coronary Artery Bypass Grafting is a surgical indication with limited oral pharmaceutical market presence, characterized by procedural dominance rather than drug-driven revenue.

N/A — unable to attribute (no product revenue data available; CABG is procedure-centric, not primarily drug-driven) marketMature→ Stable00

Key Trends

  • Clinical pipeline dominated by perioperative support and graft patency agents
  • Bristol Myers Squibb concentration signals niche specialization opportunity
  • Phase 3/4 trials indicate mature development stage with regulatory clarity

Career Verdict

This is a specialized, lower-volume pharmaceutical niche—better suited for professionals seeking deep clinical expertise in cardiac surgery support rather than broad commercial exposure.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Career Outlook

Stable

The CABG pharmaceutical market is a mature, niche segment within cardiac surgery—not expanding rapidly but offering deep expertise opportunities in perioperative care and graft optimization. Career growth will be incremental rather than explosive, with most openings concentrated in manufacturing and operational roles. This is a "specialist's" space: high barriers to entry but stable, predictable careers for those with cardiac or surgical pharmacy backgrounds.

Breaking In

Enter through manufacturing, quality assurance, or clinical operations—these roles have the highest hiring volume and lowest specialist barriers; build cardiac surgery knowledge on the job.

For Experienced Professionals

If you have cardiac surgery, cardiovascular pharmacology, or Phase 3/4 trial leadership experience, you have a valuable niche; otherwise, view this as a deep-dive specialization rather than a high-growth career accelerator.

In-Demand Skills

Cardiac physiology and surgical knowledgeQuality and manufacturing process expertiseClinical trial design (Phase 3/4 experience)Regulatory affairs (FDA cardiac device/drug combinations)Medical affairs and physician relationship management

Best For

Medical Science Liaison (cardiac surgery focus)Manufacturing/Operations ManagerClinical Operations SpecialistRegulatory Affairs (cardiac indication)Cardiac Pharmacist/Clinical Pharmacy Specialist

Hiring Landscape

$166K–$283K

Bristol Myers Squibb anchors 760 job openings in CABG-related roles, with manufacturing (38%) and medical affairs (10%) dominating demand. Clinical Operations roles command the highest salaries ($283K avg), reflecting the specialized nature of cardiac surgical support. This concentration in one company indicates that CABG specialization carries significant single-employer risk.

760
Open Roles
1
Companies Hiring
6
Departments

Top Hiring Companies

By Department

Manufacturing(38%)
$183K
Medical Affairs(10%)
$204K
Engineering(6%)
$166K
Research & Development(4%)
$181K
Clinical Operations(4%)
$283K
Data Science(2%)
$258K

Manufacturing and supply chain roles dominate; pharma professionals with operations or quality backgrounds have the strongest entry point, but diversification beyond Bristol Myers Squibb is essential for career resilience.

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Boston Scientific
Boston ScientificCA - Valencia
2 programs
2
Paclitaxel eluting stentPhase 41 trial
Paclitaxel eluting stentPhase 41 trial
Active Trials
NCT00289835Completed57Est. Oct 2008
NCT01223443Terminated125Est. Sep 2016
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
Conventional Coronary Artery BypassPhase 31 trial
Active Trials
NCT00999089Unknown616Est. Sep 2010
Martin Pharmaceuticals
1 program
1
Conventional Coronary Artery BypassPhase 3
Tenax Therapeutics
Tenax TherapeuticsCHAPEL HILL, NC
1 program
LevosimendanPHASE_31 trial
Active Trials
NCT02025621Completed882Est. Nov 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boston ScientificPaclitaxel eluting stent
Boston ScientificPaclitaxel eluting stent
Tenax TherapeuticsLevosimendan
MedtronicConventional Coronary Artery Bypass

Clinical Trials (4)

Total enrollment: 1,680 patients across 4 trials

NCT01223443Boston ScientificPaclitaxel eluting stent

Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents

Start: Apr 2010Est. completion: Sep 2016125 patients
Phase 4Terminated
NCT00289835Boston ScientificPaclitaxel eluting stent

Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial

Start: Feb 2006Est. completion: Oct 200857 patients
Phase 4Completed

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Start: Jul 2014Est. completion: Nov 2016882 patients
Phase 3Completed
NCT00999089MedtronicConventional Coronary Artery Bypass

Arrested Versus Beating Heart Techniques in Coronary Revascularisation

Start: Jan 2003Est. completion: Sep 2010616 patients
Phase 3Unknown

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.